Lankford Wade Appointed Chief Executive Officer of UpStream
A seasoned healthcare leader, Wade comes to UpStream from Summit Health/CityMD, a leading provider of primary, specialty, and urgent care, as their Chief Financial Officer. Lankford joined Summit Health at the onset of the COVID-19 pandemic and was instrumental in Summit Health/CityMD's success during the pandemic up through their recent acquisition by VillageMD. Prior to Summit, Lankford was CFO at US Anesthesia Partners. He has extensive healthcare, finance, and operations experience from earlier roles at Aetna, HealthSpring, General Atlantic Partners, and Morgan Stanley. Lankford's commitment to the healthcare industry is evident in his role on the Board and as the Chair of the Audit Committee of United Muskuloskeletal Partners, a Welsh Carson portfolio company.
Lankford shared his enthusiasm about joining UpStream, "I am excited to be joining the team at UpStream and supporting their mission of empowering patients to live happier, more independent lives. I believe in the value of the UpStream care team model and I look forward to working with our provider and health system partners to address the needs of our populations – one patient at a time."
"We are delighted to welcome
About UpStream
At the heart of UpStream is a commitment to the well-being of seniors. Through innovative healthcare solutions and an unwavering focus on patient care, UpStream stands as an industry vanguard. Central to the company's ethos is the nurturing of the physician-patient-care team relationship, a foundation that promises to elevate the quality of life for countless seniors.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lankford-wade-appointed-chief-executive-officer-of-upstream-301926551.html
SOURCE UpStream Healthcare
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beijing Review: Young People from China and the U.S. Get an Inside Look at the Future of Robotics
- ThreatMark positioned as a Leader in the SPARK Matrix™: Behavioral Biometrics and Device Intelligence Solutions 2026 by QKS Group
- NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Morgan Stanley, Vanguard, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share